XSpray Pharma AB (XSPRAY) - Net Assets
Based on the latest financial reports, XSpray Pharma AB (XSPRAY) has net assets worth Skr641.73 Million SEK (≈ $69.06 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr820.20 Million ≈ $88.27 Million USD) and total liabilities (Skr178.47 Million ≈ $19.21 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check XSpray Pharma AB asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr641.73 Million |
| % of Total Assets | 78.24% |
| Annual Growth Rate | 54.71% |
| 5-Year Change | 6.95% |
| 10-Year Change | N/A |
| Growth Volatility | 101.22 |
XSpray Pharma AB - Net Assets Trend (2015–2024)
This chart illustrates how XSpray Pharma AB's net assets have evolved over time, based on quarterly financial data. Also explore XSPRAY asset base for the complete picture of this company's asset base.
Annual Net Assets for XSpray Pharma AB (2015–2024)
The table below shows the annual net assets of XSpray Pharma AB from 2015 to 2024. For live valuation and market cap data, see market cap of XSpray Pharma AB.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr623.10 Million ≈ $67.06 Million |
-10.14% |
| 2023-12-31 | Skr693.41 Million ≈ $74.62 Million |
+24.71% |
| 2022-12-31 | Skr556.02 Million ≈ $59.84 Million |
-6.04% |
| 2021-12-31 | Skr591.75 Million ≈ $63.68 Million |
+1.57% |
| 2020-12-31 | Skr582.59 Million ≈ $62.70 Million |
+55.89% |
| 2019-12-31 | Skr373.71 Million ≈ $40.22 Million |
+23.86% |
| 2018-12-31 | Skr301.72 Million ≈ $32.47 Million |
+93.83% |
| 2017-12-31 | Skr155.66 Million ≈ $16.75 Million |
+234.94% |
| 2016-12-31 | Skr46.47 Million ≈ $5.00 Million |
+278.98% |
| 2015-12-31 | Skr12.26 Million ≈ $1.32 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to XSpray Pharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10641.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr37.14 Million | 5.96% |
| Other Comprehensive Income | Skr998.00K | 0.16% |
| Other Components | Skr1.43 Billion | 228.73% |
| Total Equity | Skr623.10 Million | 100.00% |
XSpray Pharma AB Competitors by Market Cap
The table below lists competitors of XSpray Pharma AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kuang Hong Arts Management
TWO:6596
|
$119.72 Million |
|
NS Co. Ltd
KQ:217820
|
$119.73 Million |
|
Ctek AB
ST:CTEK
|
$119.74 Million |
|
Mikro MSC Bhd
KLSE:0112
|
$119.83 Million |
|
Noroo Paint
KO:090350
|
$119.68 Million |
|
Bionet
TWO:1784
|
$119.66 Million |
|
MaxsMaking Inc. Class A Ordinary Shares
NASDAQ:MAMK
|
$119.60 Million |
|
Moller Y Perez
SN:MOLLER
|
$119.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in XSpray Pharma AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 693,413,000 to 623,097,000, a change of -70,316,000 (-10.1%).
- Net loss of 285,523,000 reduced equity.
- Share repurchases of 236,520,000 reduced equity.
- New share issuances of 236,520,000 increased equity.
- Other comprehensive income increased equity by 999,000.
- Other factors increased equity by 214,208,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-285.52 Million | -45.82% |
| Share Repurchases | Skr236.52 Million | -37.96% |
| Share Issuances | Skr236.52 Million | +37.96% |
| Other Comprehensive Income | Skr999.00K | +0.16% |
| Other Changes | Skr214.21 Million | +34.38% |
| Total Change | Skr- | -10.14% |
Book Value vs Market Value Analysis
This analysis compares XSpray Pharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.42x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 27.10x to 1.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Skr0.98 | Skr26.65 | x |
| 2016-12-31 | Skr7.25 | Skr26.65 | x |
| 2017-12-31 | Skr18.36 | Skr26.65 | x |
| 2018-12-31 | Skr21.27 | Skr26.65 | x |
| 2019-12-31 | Skr24.34 | Skr26.65 | x |
| 2020-12-31 | Skr33.54 | Skr26.65 | x |
| 2021-12-31 | Skr30.48 | Skr26.65 | x |
| 2022-12-31 | Skr26.15 | Skr26.65 | x |
| 2023-12-31 | Skr26.07 | Skr26.65 | x |
| 2024-12-31 | Skr18.80 | Skr26.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently XSpray Pharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.28x
- Recent ROE (-45.82%) is below the historical average (-25.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -98.60% | -332.17% | 0.24x | 1.22x | Skr-13.32 Million |
| 2016 | -8.82% | -517.30% | 0.02x | 1.12x | Skr-8.74 Million |
| 2017 | -8.48% | -3980.86% | 0.00x | 1.04x | Skr-28.76 Million |
| 2018 | -7.66% | -8338.63% | 0.00x | 1.04x | Skr-53.27 Million |
| 2019 | -12.27% | 0.00% | 0.00x | 1.07x | Skr-83.21 Million |
| 2020 | -8.98% | 0.00% | 0.00x | 1.04x | Skr-110.56 Million |
| 2021 | -16.34% | 0.00% | 0.00x | 1.05x | Skr-155.88 Million |
| 2022 | -23.43% | 0.00% | 0.00x | 1.05x | Skr-185.87 Million |
| 2023 | -25.91% | 0.00% | 0.00x | 1.10x | Skr-249.01 Million |
| 2024 | -45.82% | 0.00% | 0.00x | 1.28x | Skr-347.83 Million |
Industry Comparison
This section compares XSpray Pharma AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,054,194
- Average return on equity (ROE) among peers: -81.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| XSpray Pharma AB (XSPRAY) | Skr641.73 Million | -98.60% | 0.28x | $119.72 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $14.33 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the tr… Read more